Results 81 to 90 of about 720,445 (328)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. [PDF]

, 2013
PurposeMET alterations including amplifications and nucleotide variations have been associated with resistance to therapy and aggressive clinical behavior.Experimental designThe medical records of patients presenting to the University of Texas MD ...
De Melo Galgiato, Debora, Falchook, Gerald S, Fu, Siqing, Hess, Kenneth, Hong, David S, Jardim, Denis L Fontes, Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Tang, Chad, Tsimberidou, Apostolia M, Westin, Shannon N, Wheler, Jennifer J, Zinner, Ralph G   +13 more
core   +3 more sources

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

The ovarian cancer oncobiome [PDF]

Oncotarget, 2017
Humans and other mammals are colonized by microbial agents across the kingdom which can represent a unique microbiome pattern. Dysbiosis of the microbiome has been associated with pathology including cancer. We have identified a microbiome signature unique to ovarian cancers, one of the most lethal malignancies of the female reproductive system ...
Banerjee, S., Tian, T., Wei, Z., Shih, N., Feldman, M.D., Alwine, J.C., Coukos, G., Robertson, E.S.   +7 more
openaire   +3 more sources

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

Nature Communications, 2018
Some anticancer drugs target cell microtubules inhibiting mitosis and cell division. Here, the authors show that CRMP2 induces microtubule bundling and that this activity is regulated by the FER kinase, thus providing a rationale for targeting FER in ...
Yiyan Zheng, Ritika Sethi, Lingegowda S. Mangala, Charlotte Taylor, Juliet Goldsmith, Ming Wang, Kenta Masuda, Mohammad Karaminejadranjbar, David Mannion, Fabrizio Miranda, Sandra Herrero-Gonzalez, Karin Hellner, Fiona Chen, Abdulkhaliq Alsaadi, Ashwag Albukhari, Donatien Chedom Fotso, Christopher Yau, Dahai Jiang, Sunila Pradeep, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Stefan Knapp, Nathanael S. Gray, Leticia Campo, Kevin A. Myers, Sunanda Dhar, David Ferguson, Robert C. Bast, Anil K. Sood, Frank von Delft, Ahmed Ashour Ahmed   +30 more
doaj   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Gonadotropins and Ovarian Cancer [PDF]

Endocrine Reviews, 2007
Ovarian epithelial cancer (OEC) accounts for 90% of all ovarian cancers and is the leading cause of death from gynecological cancers in North America and Europe. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies.
Wong, AST, Leung, PCK, Huang, HF, Choi, JH   +3 more
openaire   +5 more sources

Successful Fertility Preservation Using Ex vivo Oocyte Retrieval and Transportation in a Case of Stage IB3 Cervical Cancer with a Risk of Ovarian Metastasis

Fertility & Reproduction
This case involved a 31-year-old woman with stage IB3 cervical cancer and suspected obturator lymph node metastasis. The cervical tumor size exceeded 4 cm.
Yuta Kasahara, Tomoko Hashimoto, Airi Kobayashi, Noriyuki Okuyama, Yuriko Fukuoka, Shogo Nishino, Motoko Kanno, Hiroyuki Kanao, Koichi Kyono   +8 more
doaj   +1 more source

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. [PDF]

, 2017
PurposeMany women with an elevated risk of hereditary breast and ovarian cancer have previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a subset has hereditary susceptibility to cancer and requires further testing.
Adams, Sophie B, Chan, Salina, Crawford, Beth, Gil, Elad, Leitner, Ofri, Ryan, Lauren, Sittler, Taylor, van 't Veer, Laura, van den Akker, Jeroen   +8 more
core   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

The epidemiology of ovarian cancer [PDF]

International Journal of Gynecological Cancer, 2001
The overall mortality from epithelial ovarian cancer has changed little over the past 20 years. Despite the widely heralded introduction of new chemotherapy agents such as the taxanes and increased interest in the possibility of screening for early-stage disease the overall 5-year survival rate remains static at about 30%.
Edmondson, R J, Monaghan, J M
openaire   +3 more sources